Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Dulaglutide-induced cerebral venous thrombosis in a patient with type 2 diabetes mellitus.

Rajput R, Pathak V, Yadav PK, Mishra S.

BMJ Case Rep. 2018 Nov 8;2018. pii: bcr-2018-226346. doi: 10.1136/bcr-2018-226346.

PMID:
30413453
2.

Dulaglutide for type 2 diabetes.

[No authors listed]

Aust Prescr. 2018 Oct;41(5):166-168. doi: 10.18773/austprescr.2018.052. Epub 2018 Sep 11. Review. No abstract available.

3.

Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK.

Viljoen A, Hoxer CS, Johansen P, Malkin S, Hunt B, Bain SC.

Diabetes Obes Metab. 2018 Oct 25. doi: 10.1111/dom.13564. [Epub ahead of print]

PMID:
30362224
4.

Pyoderma gangrenosum associated with dulaglutide therapy.

Hamann CR, Chung C, Kaffenberger BH.

Int J Dermatol. 2018 Oct 21. doi: 10.1111/ijd.14272. [Epub ahead of print] No abstract available.

PMID:
30345551
5.

[The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes].

Shimoda K, Hoshino T, Morisaki T, Shiotsu K, Mizuno Y.

Yakugaku Zasshi. 2018;138(10):1323-1327. doi: 10.1248/yakushi.18-00060. Japanese.

6.

Renoprotective effects of dulaglutide in patients with T2DM and CKD.

Sorensen CM, Holst JJ.

Nat Rev Nephrol. 2018 Nov;14(11):659-660. doi: 10.1038/s41581-018-0055-x. No abstract available.

PMID:
30171207
7.

Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.

Wang W, Nevárez L, Filippova E, Song KH, Tao B, Gu L, Wang F, Li P, Yang J.

Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13506. [Epub ahead of print]

PMID:
30129089
8.

Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.

Boye KS, Mody R, Wu J, Lage MJ, Botros FT, Woodward B.

Clin Ther. 2018 Aug;40(8):1396-1407. doi: 10.1016/j.clinthera.2018.07.002. Epub 2018 Aug 6.

9.

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.

Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dannoura M, Cho KY, Kurihara Y, Manda N, Aoki S, Atsumi T, Miyoshi H.

J Diabetes Investig. 2018 Aug 4. doi: 10.1111/jdi.12906. [Epub ahead of print]

10.

Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.

Matsushita M, Chujo D, Tonoike M, Kajio H.

Diabetes Ther. 2018 Oct;9(5):2127-2132. doi: 10.1007/s13300-018-0474-5. Epub 2018 Jul 28.

11.

Dulaglutide.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

12.

The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis.

Yajima T, Yajima K, Takahashi H, Yasuda K.

J Diabetes Complications. 2018 Aug;32(8):759-763. doi: 10.1016/j.jdiacomp.2018.05.018. Epub 2018 Jun 1.

PMID:
29937137
13.

Dulaglutide and renal protection in type 2 diabetes.

Cherney DZI, Verma S, Parker JD.

Lancet Diabetes Endocrinol. 2018 Aug;6(8):588-590. doi: 10.1016/S2213-8587(18)30125-6. Epub 2018 Jun 14. No abstract available.

PMID:
29910025
14.

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT.

Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14.

PMID:
29910024
15.

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.

Cusi K, Sattar N, García-Pérez LE, Pavo I, Yu M, Robertson KE, Karanikas CA, Haupt A.

Diabet Med. 2018 Oct;35(10):1434-1439. doi: 10.1111/dme.13697. Epub 2018 Jun 22.

PMID:
29869810
16.

Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.

Garg A, Kumar A.

Curr Drug Saf. 2018;13(3):165-170. doi: 10.2174/1574886313666180601082412.

PMID:
29852875
17.

Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".

Leslie RD, Pozzilli P, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC.

Diabetes Obes Metab. 2018 Sep;20(9):2319-2320. doi: 10.1111/dom.13366. Epub 2018 Jun 10. No abstract available.

PMID:
29781106
18.

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data.

Kugler AJ, Thiman ML.

Diabetes Metab Syndr Obes. 2018 May 9;11:187-197. doi: 10.2147/DMSO.S134960. eCollection 2018. Review.

19.
20.

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.

Chen YH, Huang CN, Cho YM, Li P, Gu L, Wang F, Yang J, Wang WQ.

Diabetes Obes Metab. 2018 Sep;20(9):2121-2130. doi: 10.1111/dom.13340. Epub 2018 Jun 5.

Supplemental Content

Loading ...
Support Center